Published in Clin Cancer Res on March 01, 2000
Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas (SA02) | NCT00881595
Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res (2008) 1.94
Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol (2008) 1.57
MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res (2010) 1.40
Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem (2010) 1.30
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J Neurooncol (2008) 1.28
Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol (2010) 1.22
Temozolomide induces senescence but not apoptosis in human melanoma cells. Br J Cancer (2007) 1.20
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol (2008) 1.13
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. Br J Cancer (2010) 1.05
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol (2009) 1.03
Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. Br J Cancer (2005) 0.98
Role of temozolomide in pediatric brain tumors. Childs Nerv Syst (2006) 0.92
Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study. Wien Klin Wochenschr (2013) 0.88
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group. Pediatr Blood Cancer (2010) 0.88
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nat Commun (2015) 0.87
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer (2013) 0.87
IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression. Mol Cancer Ther (2008) 0.86
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res (2014) 0.85
Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy. Neuro Oncol (2011) 0.83
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J Natl Cancer Inst (2015) 0.83
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer (2013) 0.82
Antitumor effect of fibrin glue containing temozolomide against malignant glioma. Cancer Sci (2014) 0.78
Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models. Br J Cancer (2010) 0.77
Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. Neuro Oncol (2013) 0.77
Efficacy and safety of antitumor agents plus radiotherapy compared with radiotherapy alone for brain metastases from lung cancer. Mol Clin Oncol (2017) 0.75
Pretreatment but not subsequent coincubation with midazolam reduces the cytotoxicity of temozolomide in neuroblastoma cells. BMC Anesthesiol (2015) 0.75
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation. Front Oncol (2015) 0.75
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (1994) 10.45
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (1997) 7.07
Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med (1989) 5.81
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A (1990) 4.42
Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med (1993) 4.28
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol (1999) 3.30
PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res (1997) 3.15
mTOR and cancer therapy. Oncogene (2006) 3.07
Coding of border ownership in monkey visual cortex. J Neurosci (2000) 2.92
Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol (1999) 2.69
ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) Oncogene (1997) 2.44
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
alpha-Amylase inhibitory activity of some Malaysian plants used to treat diabetes; with particular reference to Phyllanthus amarus. J Ethnopharmacol (2006) 2.38
Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol (1998) 2.32
Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ (1990) 2.24
Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol (1999) 2.23
Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med (2001) 2.20
Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res (1990) 2.15
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol (1995) 2.09
Amino acid-dependent control of p70(s6k). Involvement of tRNA aminoacylation in the regulation. J Biol Chem (1999) 2.08
Successful therapy for trilateral retinoblastoma. Am J Ophthalmol (1992) 2.03
Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol (2001) 2.03
Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ (1995) 2.00
Sociodemographic and psychosocial factors in childhood as predictors of adult mortality. Am J Public Health (1995) 1.98
Predicting patient satisfaction from physicians' nonverbal communication skills. Med Care (1980) 1.95
Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer (2004) 1.92
Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res (1988) 1.89
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res (1999) 1.89
Amplification of the gli gene in childhood sarcomas. Cancer Res (1989) 1.84
War Experiences with the Nonsuture Technic of Anastomosis in Primary Arterial Injuries. Ann Surg (1947) 1.84
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst (1998) 1.82
Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. J Clin Oncol (1998) 1.79
Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res (1997) 1.77
Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol (1998) 1.76
Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res (1994) 1.75
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res (2001) 1.65
The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene (1996) 1.65
Infrequent p53 gene mutations in medulloblastomas. Cancer Res (1991) 1.62
Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther (2012) 1.62
Variations in phosphokinase activities during the cell cycle in synchronous populations of HeLa cells. Nature (1965) 1.61
A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet (1987) 1.60
Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res (1990) 1.58
Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry (1996) 1.58
Alterations of the TP53 gene in human gliomas. Cancer Res (1994) 1.58
Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res (2001) 1.56
Myogenic regulatory protein expression in adult soft tissue sarcomas. A sensitive and specific marker of skeletal muscle differentiation. Am J Pathol (1994) 1.55
Representation of stereoscopic edges in monkey visual cortex. Vision Res (2000) 1.52
Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. J Neuropathol Exp Neurol (1985) 1.51
Human lymphoblasts contain DNA glycosylase activity excising N-3 and N-7 methyl and ethyl purines but not O6-alkylguanines or 1-alkyladenines. Proc Natl Acad Sci U S A (1981) 1.50
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer (2009) 1.49
Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene (1995) 1.49
Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res (1999) 1.47
Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol (2000) 1.44
Monoclonal antibodies to the myogenic regulatory protein MyoD1: epitope mapping and diagnostic utility. Cancer Res (1992) 1.43
Etoposide: an update. Clin Pharm (1989) 1.41
The "disease-prone personality". A meta-analytic view of the construct. Am Psychol (1987) 1.41
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol (1999) 1.41
Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol (1998) 1.41
The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol (1999) 1.40
Do non-scientists really live longer? Lancet (1994) 1.39
Repair of alkylated DNA in mammalian cells. Nature (1968) 1.38
Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. Am J Pathol (1990) 1.34
Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther (2001) 1.33
Marital history at midlife as a predictor of longevity: alternative explanations to the protective effect of marriage. Health Psychol (1996) 1.33
Psychological predictors of heart disease: a quantitative review. Psychol Bull (1987) 1.33
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A (2000) 1.32
Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope (1998) 1.32
Chromosomal assignment and genomic structure of Il15. Genomics (1995) 1.31
Role of murine tumor models in cancer treatment research. Cancer Res (1986) 1.30
Anti-inflammatory activities of the methanol extracts and an isolated furanoditerpene constituent of Sphenocentrum jollyanum Pierre (Menispermaceae). J Ethnopharmacol (2005) 1.29
Mechanisms of resistance to rapamycins. Drug Resist Updat (2001) 1.28
In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol (2000) 1.28
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (1995) 1.27
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res (2000) 1.27
p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res (2001) 1.26
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol (1997) 1.25
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol (1992) 1.24
P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol (2000) 1.22
Structural chromosomal abnormalities in human medulloblastoma. Cancer Genet Cytogenet (1988) 1.22
Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res (1979) 1.21
Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys (1993) 1.20
Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene. Nucleic Acids Res (1991) 1.19
Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest (1994) 1.19
"Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol (2000) 1.19
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol (1996) 1.18
Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol (1995) 1.18
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin Cancer Res (2000) 1.17
Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer (2006) 1.17
Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res (1987) 1.17
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. J Med Chem (1996) 1.17